Approval · Notice of Compliance 2376 · 2001
FEMARA: Notice of Compliance 2376
Issued May 11, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2376
- Date
- May 11, 2001
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: first-line therapy in postmenopausal women with advanced breast cancer
- Therapeutic class
- Non-steroidal aromatase inhibitor; inhibitor of estrogen biosynthesis; antitumour agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FEMARA | Not yet assigned | — |
Medicinal ingredients
- LETROZOLE 2.5 MG per TAB